Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells
Incretin-based multi-agonists, such as tirzepatide and retatrutide, target two or more receptors among GLP-1, GIP, and GCGR to enhance insulin secretion, improve fat metabolism, and increase energy expenditureultimately achieving greater weight loss and metabolic improvement
Given the significant unmet need for novel therapeutic interventions in AS, particularly as many patients still progress to KF despite current treatments like RASi, GLP-1 RAs may offer an innovative strategy to delay KF in AS, potentially addressing both metabolic and inflammatory pathways involved in CKD progression [40, 42, 56]
Regular follow-up and long-term care help keep blood sugar levels steady, support healthy body weight, and overall health, because GLP-1 medicines alone cannot manage diabetes or obesity 5